TrialFrontiers in immunology2026

MesenSistem-EB: systemic haploidentical mesenchymal stem cell therapy in recessive dystrophic epidermolysis bullosa associated with clinical benefits and correlated with MCP1 and sCD40L dynamics.

Rocío Maseda et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.